Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, gives an update on the BRUIN trial (NCT03740529), which found that patients with chronic lymphocytic leukemia (CLL) responded well to pirtobrutinib after a covalent BTK inhibitor. There are many extension studies that combine pirtobrutinib with other agents in a time-limited approach. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть